Clinical Trial: JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07154368) titled 'JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.' on Aug. 19.

Brief Summary: The primary purpose of the study was to compare progression-free survival of JYP0322 vs. platinum-based doublet chemotherapy in patients previously treated with ROS1-TKIs. Patients in the chemotherapy arm are given the option to switch to JYP0322 after BICR confirmed progressive disease (PD), while also have the choice to pursue with other drugs after discussing with their physicians.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer

Intervention: ...